Clinical Trial Uncertainty
Success depends on positive trial outcomes and regulatory approvals.
- Materiality
- high
Karolinska Development
Karolinska Development is a Nordic life sciences investment company based in Solna, Sweden. The company focuses on identifying and investing in medical innovations, particularly in therapeutic and MedTech companies. Its business model involves financing these companies until they achieve proof-of-concept or positive operating profit, after which exit options are evaluated. The portfolio consists of companies developing treatments for severe diseases, with several drug candidates in various clinical trial phases.
| % | |
|---|---|
| Therapeutic Investments | 60% Investments in companies developing innovative treatments for severe diseases. |
| MedTech Investments | 30% Investments in medical technology companies until they achieve positive operating profit. |
| Earn-out Agreements | 10% Agreements with acquirers for milestone payments during drug development and commercialization. |
Karolinska Development primarily collaborates with professional life science investors and syndicates to co-invest in...
- Life Science Investorsprimary
Co-invest in therapeutic and MedTech companies to share risk and reward.
- Pharmaceutical Companiesprimary
Acquire or license drug candidates after proof-of-concept is demonstrated.
- MedTech Firmssecondary
Receive financial support until achieving positive operating profit.
Karolinska Development is headquartered in Solna, Sweden, and operates primarily within the Nordic region...
- •Headquartered in Solna, Sweden, with a focus on the Nordic region.
- •Investments primarily in European-based companies.
- •Presence in the United States through partnerships and sales offices.
- •Geographic focus leverages regional expertise and networks.
Karolinska Development's strategic priorities include enhancing the value of its portfolio companies through clinical...
01
Enhance Portfolio Valuemedium-term
To achieve significant clinical milestones and strategic exits.
02
Strengthen Financial Positionshort-term
To ensure liquidity and support future investments.
Karolinska Development faces several risks, including the inherent uncertainties of clinical trials and regulatory...
Market Conditions
Competitive pressures and market dynamics affect exit opportunities.
- Materiality
- high
Fair Value Valuation
high
Revenue Recognition Timing
medium
Skanska
SKA-B.ST · Industrials
Skanska AB is a global construction and project development company headquartered in Sweden.
Carasent
CARA.ST · Health Care
Carasent is a Swedish company specializing in digital services for the healthcare industry.
Nordicus Partners Corp
NORD · Services-Management Consulting Services
Nordicus Partners Corp is a U.S.-listed business accelerator and holding company focused on Nordic life sciences ventures.
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Greenland Mines Ltd
GRML · Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd is a U.S.-based development-stage life sciences company that has not yet generated operating revenue.
Solana Co
HSDT · Finance Services
Solana Co is a U.S.-based public company organized around a Solana digital asset treasury strategy, with Solana (SOL) as its primary treasury reserve asset.
: 11/08/2026